We further identified an FGFR inhibitor that decreased expression of ETV4 and showed efficacy both as a single agent against SCLC and in combination with cisplatin and etoposide to slow regrowth both in vitro and in vivo. Here, ETV4 is linked to small cell lung carcinoma.